Company / Capital Expenditures
Kura Oncology, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$6.6M
FY2025
5-year range
$168.0K / $6.6M
FY2021-FY2025
Trend
+1306.4%
vs FY2024
Sector context
#67 of 194
Health Care
What the data says
Capital Expenditures changed +1306% YoY in FY2025, a notable deviation from the 5-year average annual change of +264%.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +25.0%.
Improved from $168,000 to $7M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +119.7%
- 5-Year CAGR
- +25.0%
- 10-Year CAGR
- -
Sector benchmark
#67 of 194 in Health CareTop 35% of 194This company $6.6M Sector average $117.5M
▼
-94.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.0%, indicating consistent growth.
- In FY2025, capital expenditures increased 1306.4% year-over-year.
- Ranks #67 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.6M | +1306.4% |
| FY2024 | $472.0K | +181.0% |
| FY2023 | $168.0K | -73.2% |
| FY2022 | $626.0K | -45.4% |
| FY2021 | $1.1M | -47.2% |
| FY2020 | $2.2M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026